Factors affecting anemia management in hemodialysis patients: A single-center experience

Hemodialysis International

Volumn 12, Issue 3, 2008, Pages 336-341

  Spiegel, David M ^a   Gitlin, Matthew ^b   Mayne, Tracy ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b AMGEN INC   (United States)

Author keywords

Anemia management; End stage kidney disease; EPO; Erythropoietin

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; FACTUAL DATABASE; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PRESCHOOL CHILD; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 55749102068     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00278.x     Document Type: Article

References (10)

1. U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
2. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44:94-111.
3. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005; 46:481-488.
4. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, DeOreo PB. Hemoglobin variability in epoetintreated hemodialysis patients. Kidney Int. 2003; 64: 1514-1521.
5. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68:1337-1343.
6. Lacson E, Ofsthun N, Lazarus JM. Effects of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003; 41:111-124.
7. Barany P, Muller HJ. Maintaining control over haemoglobin levels: Optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant. 2007; 22:iv10-18.
8. Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004; 43:649-659.
9. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp Biol Med. 2003; 228:1-14.
10. Daniel DE, Miskulin DC, Seefeld K, et al. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am S Nephol. 2007; 18:3184-3191.